The administration of interleukin-2 (IL-2) may induce complete remissions in acute myelogenous leukemia (AML) patients with a low proportion of residual bone marrow (BM) blasts. To confirm this preliminary observation, we treated 14 AML patients with advanced disease and with a residual BM blastosis that ranged between 7% and 24% with repeated 5-day cycles of high-dose recombinant IL-2 administered by daily continuous intravenous infusion. Patients who responded have been subsequently submitted to a monthly maintenance scheme with subcutaneous IL-2 at lower doses. While using this schedule and closely monitoring clinical and laboratory conditions, side effects were acceptable and no toxic deaths recorded. Eight of the 14 patients treated with high-dose IL-2 obtained a complete remission (CR). Five remain in persistent CR (four in third CR and one in fourth CR) after a median follow-up time of 32 months (14, 30, 32, 33, and 68 months, respectively). In all five patients, the IL-2-induced remission is the longest in the natural history of the disease. These findings show that IL-2 displays an antileukemic effect in AML with limited residual disease, and suggest that IL-2 should be considered a therapeutic option for resistant or relapsed AML patients.
Interleukin-2 may induce prolonged remissions in advanced acute myelogenous leukemia
- Share Icon Share
- Tools Icon Tools
- Search Site
- PDF LinkPDF
G Meloni, R Foa, M Vignetti, A Guarini, S Fenu, S Tosti, AG Tos, F Mandelli; Interleukin-2 may induce prolonged remissions in advanced acute myelogenous leukemia. Blood 1994; 84 (7): 2158–2163. doi: https://doi.org/10.1182/blood.V84.7.2158.bloodjournal8472158
Download citation file: